A recent comprehensive meta-analysis concluded that pCR followed by NAC was associated with significantly better event-free survival (EFS) and overall survival (OS), especially for patients with triple-negative and HER2 + breast cancer. The tumor response effect observed in the pCR group was similar in adjuvant chemotherapy and NAC patients [15]. This evidence concerns the gene ERBB2 and neoplasm.